Navigation Links
Hospira Reports First-Quarter 2013 Results
Date:5/1/2013

>$46.7

(354.0)%

$101.2

$104.2

(2.9)%Diluted (Loss) Earnings per Share

$(0.46)

$0.24

(291.7)%

$0.52

$0.47

10.6%Statistics (as a % of Net Sales)Gross Profit (Net Sales less

Cost of Products Sold)

17.0%

31.1%36.4%

37.0%(Loss) Income from

Operations

(13.4)%

4.8%10.2%

10.8%Results under GAAP include items as detailed in the schedules attached to this press release.

Adjusted* net sales (excluding the impact of customer sales allowances associated with the company's device strategy) were $988 million in the first quarter of 2013, an increase of 2.3 percent compared to the first quarter of 2012. Continued strong U.S. sales of Precedex™ and higher pricing on certain Specialty Injectable Pharmaceuticals (SIP) products in the U.S. drove the majority of the increase. These factors more than offset pricing erosion of certain newer U.S. SIP products and lower device sales as a result of an expanded import alert by the U.S. Food and Drug Administration, announced on February 14, 2013. On a GAAP basis, net sales in the quarter were $884 million and include the impact of charges associated with the company's device strategy, announced May 1, 2013.

Adjusted* income from operations decreased 2.9 percent to $101 million in the first quarter of 2013, compared to $104 million in the first quarter of 2012. The decline primarily reflects the impact of costs associated with higher year-over-year manufacturing costs related to quality initiatives and higher research and development (R&D) spending. On a GAAP basis, loss from operations was $119 million compared to income from operations of $47 million in the first quarter of 2012. The decrease was mainly due to the impact of charges related to the company's new device strategy.

The effective tax rate on an adjusted basis* in the quarter was 1.0 percent co
'/>"/>

SOURCE Hospira, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Hospira to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
2. Hospira Reports First-Quarter 2012 Results
3. Hospira to Present at Upcoming Investor Conferences
4. I.V. Clinical Integration Helps Deliver Safety, Efficiency And Financial Benefits; Hospira Shares Snapshot Of Results, Process
5. Hospira and Lancaster General Hospital Honored for Patient Safety Initiatives
6. Hospira to Host Conference Call for Second-quarter 2012 Results
7. Hospira Expands Board of Directors With Election of Dennis M. Fenton
8. Hospira Reports Second-Quarter 2012 Results
9. Hospira to Acquire Active Pharmaceutical Ingredient Manufacturing and R&D Facilities
10. Hospira Reports Third-Quarter 2012 Results
11. Hospira to Present at the J.P. Morgan 31st Annual Healthcare Conference Jan. 8, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... NEW YORK , Aug. 28, ... a new market research report is ... ADHD Therapeutics to 2020 - Broadened ... to Drive Market Growth despite Patent ... ADHD Therapeutics to ...
(Date:8/28/2014)... Aug. 28, 2014  Critical Process Filtration, Inc. ... today announces the expansion of their Technical Services ... Filtration now offers customers and potential customers services ... filter failure analyses (even for competitor filters) and ... hallmark services of system benchmarking and cost/performance optimization. ...
(Date:8/28/2014)... Calif. , Aug. 28, 2014 Amgen ... of a Biologics License Application (BLA) to the U.S. ... for the treatment of high cholesterol. Evolocumab is an ... subtilisin/kexin type 9 (PCSK9), a protein that reduces the ... "bad" cholesterol, from the blood. 1 ­ ...
Breaking Medicine Technology:ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 2ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 3ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 4ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 5ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 6ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 7ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 8Critical Process Filtration, Inc. Announces Expanded Technical Services and Validation Support 2Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 2Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 3Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 4Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 5Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 6Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 7Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 8Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 9
... -- American Oriental Bioengineering, Inc. (NYSE: AOB ) ... (the "NYSE") has notified the Company that it is not ... to timely file its Annual Report on Form 10-K with ... rules, when a Company does not comply with annual report ...
...  In conjunction with its first quarter 2012 earnings release (expected to be ... CVD ) is pleased to invite you to listen to its ... on Thursday, May 3, 2012 at 9:00 a.m. ET. , ... and Slide Presentation , , , , When: , , , ...
Cached Medicine Technology:American Oriental Bioengineering Inc. Receives NYSE Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard 2
(Date:8/28/2014)... Mass., (PRWEB) August 28, 2014 BCC ... SURGICAL NAVIGATION SYSTEMS: TECHNOLOGIES AND GLOBAL MARKETS , ... at $419.7 million in 2013. Driven by the need ... by medical tourism in emerging geographies, the market is ... annual growth rate (CAGR) of 8.5% from 2013 through ...
(Date:8/28/2014)... Albany, New York (PRWEB) August 28, 2014 ... is currently perceived with great interest among other healthcare ... due to the high demand in vaccine with respect ... also highly in demand due to an improved understanding ... individuals across the United States. It has led to ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Canadian Linen ... company in North America, today announced the launch of ... makes doing business with Canadian Linen even easier and ... customers to access account information online and better communicate ... portal include the ability to:, , ...
(Date:8/28/2014)... AmeriPride Services, a leading textile services ... launch of its new Customer Portal, an online resource ... more convenient for customers. The industry-leading digital tool allows ... with the company. , Features of the new customer ... Access, download and pay bills online , ...
(Date:8/28/2014)... August 28, 2014 Parker Waichman LLP, ... many years fighting to ensure that the heroes of ... provide coverage to WTC victims who developed 9/11-related cancer ... Government Accountability Office (GAO). According to a statement issued ... the report is entitled “World Trade Center Health Program: ...
Breaking Medicine News(10 mins):Health News:Global Market for Surgical Navigation Systems Expected to Reach $631.9 Million in 2018; ENT Systems Segment Leading With 10.4% CAGR 2Health News:Global Market for Surgical Navigation Systems Expected to Reach $631.9 Million in 2018; ENT Systems Segment Leading With 10.4% CAGR 3Health News:U.S. Vaccine Market: Opportunities and Threats by Transparency Market Research 2Health News:U.S. Vaccine Market: Opportunities and Threats by Transparency Market Research 3Health News:Canadian Linen and Uniform Service Launches New Customer Portal 2Health News:Canadian Linen and Uniform Service Launches New Customer Portal 3Health News:AmeriPride Services Launches New Customer Portal 2Health News:AmeriPride Services Launches New Customer Portal 3Health News:GAO Report Reaffirms Decision to Add Cancers to List of Illnesses Covered under the Zadroga Act, Parker Waichman LLP Comments 2Health News:GAO Report Reaffirms Decision to Add Cancers to List of Illnesses Covered under the Zadroga Act, Parker Waichman LLP Comments 3
... New research challenges the previously held belief that infants' ... new study finds the brain's left hemisphere plays the ... immediately after birth. ,Researchers are using functional ... activity in response to speech. They say this is ...
... try to avoid getting it, but researchers say common cold ... genetically engineer the common cold virus so that //it kills ... They did this by modifying one gene, so the virus ... the activity of another gene to ensure that the virus ...
... Government guidelines on the treatment of asthma have long ... for people with persistent forms of the condition.But reports ... people -- including parents of asthmatic children -- to ... growth retardation in children, weak bones in children and ...
... therapeutic option for patients with complicated type 1 diabetes, ... // Now, a new study finds ... worse survival than patients on the transplant waiting list ... Association supports a pancreatic transplant for patients who have ...
... a vaccine made from the common cold virus may induce ... the Centers for Disease Control and Prevention injected six monkeys ... parts of the SARS coronavirus. A new form of the ... were given a second vaccine 28 days later, and researchers ...
... women with diabetes have a higher risk of depression., ... 60 and 79. The participants were divided //into two ... the second included those without diabetes. Women who did ... groups, based on their levels of insulin resistance. ...
Cached Medicine News:Health News:New Technique to Study Infants Brain. 2Health News:Benefits and Risks of Asthma Treatment Questioned 2Health News:Pancreas Transplant for Diabetics 2
... GV is a sterile, non-pyrogenic, transparent ... noninflammatory, high molecular weight (average = ... hyaluronate. Healon GV contains 14 mg/mL ... a physiological sodium chloride-phosphate buffer (pH ...
... PROVISC ophthalmic viscosurgical device ... is characterized by high molecular ... surface tension. It provides excellent ... and is easily removed. It ...
... a product comes along that forever raises ... category. The new StealthStation TREON plus Treatment ... Built on the phenomenal success of the ... system in the worldthe new TREON plus ...
... the DigiCat Imager ("DCI") to provide rapid, ... The DCI can measure the cataract and ... objective, appropriate and timely surgical decision can ... technology is especially useful in todays healthcare ...
Medicine Products: